Henderson Pritchett Jane's most recent trade in CARGO Therapeutics Inc was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 9,398 | 9,398 (0%) | 0% | 0 | Common Stock | |
| Apogee Therapeutics Inc. | Jane Pritchett Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 124,962 | 124,962 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc. | Jane Pritchett Henderson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 23 Aug 2024 | 6,000 | 200,871 | - | 48.3 | 289,560 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2024 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 39,402 | 39,402 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 19,785 | 19,785 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc. | Henderson Pritchett Jane | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 175,345 | 175,345 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 16 Jun 2023 | 40,000 | 40,000 (0%) | 0% | 7.0 | 280,400 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 40,000 | 14,797 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Sale of securities on an exchange or to another person at price $ 54.46 per share. | 16 Jun 2023 | 22,498 | 0 (0%) | 0% | 54.5 | 1,225,291 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Sale of securities on an exchange or to another person at price $ 53.79 per share. | 16 Jun 2023 | 17,502 | 22,498 (0%) | 0% | 53.8 | 941,394 | Common Stock |
| Akero Therapeutics Inc | Jane Pritchett Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Invivyd Inc | Jane Pritchett Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2022 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) |